XNYS
WST
Market cap16bUSD
Jul 10, Last price
229.23USD
1D
1.35%
1Q
8.79%
Jan 2017
170.22%
Name
West Pharmaceutical Services Inc
Chart & Performance
Profile
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 2,893,200 -1.92% | 2,949,800 2.18% | 2,886,900 1.95% | |||||||
Cost of revenue | 1,963,800 | 1,889,000 | 1,809,200 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 929,400 | 1,060,800 | 1,077,700 | |||||||
NOPBT Margin | 32.12% | 35.96% | 37.33% | |||||||
Operating Taxes | 107,500 | 122,300 | 114,700 | |||||||
Tax Rate | 11.57% | 11.53% | 10.64% | |||||||
NOPAT | 821,900 | 938,500 | 963,000 | |||||||
Net income | 492,700 -16.97% | 593,400 1.28% | 585,900 -11.47% | |||||||
Dividends | (59,100) | (57,000) | (54,100) | |||||||
Dividend yield | 0.24% | 0.21% | 0.30% | |||||||
Proceeds from repurchase of equity | (566,600) | (451,200) | (194,000) | |||||||
BB yield | 2.35% | 1.70% | 1.09% | |||||||
Debt | ||||||||||
Debt current | 17,900 | 169,400 | 18,200 | |||||||
Long-term debt | 384,100 | 259,500 | 408,700 | |||||||
Deferred revenue | 2,100 | |||||||||
Other long-term liabilities | 105,800 | 106,700 | 96,800 | |||||||
Net debt | (284,700) | (635,000) | (672,300) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 653,400 | 776,500 | 724,000 | |||||||
CAPEX | (377,000) | (362,000) | (284,600) | |||||||
Cash from investing activities | (378,700) | (368,700) | (288,200) | |||||||
Cash from financing activities | (622,600) | (459,600) | (293,600) | |||||||
FCF | 688,100 | 602,000 | 741,500 | |||||||
Balance | ||||||||||
Cash | 484,600 | 853,900 | 894,300 | |||||||
Long term investments | 202,100 | 210,000 | 204,900 | |||||||
Excess cash | 542,040 | 916,410 | 954,855 | |||||||
Stockholders' equity | 3,717,300 | 3,398,400 | 2,823,600 | |||||||
Invested Capital | 2,548,360 | 2,397,990 | 2,108,345 | |||||||
ROIC | 33.23% | 41.65% | 48.05% | |||||||
ROCE | 29.88% | 31.88% | 35.02% | |||||||
EV | ||||||||||
Common stock shares outstanding | 73,700 | 75,300 | 75,800 | |||||||
Price | 327.56 -6.97% | 352.12 49.62% | 235.35 -49.82% | |||||||
Market cap | 24,141,172 -8.95% | 26,514,636 48.63% | 17,839,530 -50.15% | |||||||
EV | 23,856,472 | 25,879,636 | 17,167,230 | |||||||
EBITDA | 1,084,800 | 1,198,100 | 1,198,300 | |||||||
EV/EBITDA | 21.99 | 21.60 | 14.33 | |||||||
Interest | 3,000 | 9,000 | 7,900 | |||||||
Interest/NOPBT | 0.32% | 0.85% | 0.73% |